Author
Masashi Mizokami
Other affiliations: National Institute of Advanced Industrial Science and Technology, University of Florida
Bio: Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.
Topics: Hepatitis B virus, Hepatitis C virus, Hepatitis B, HBsAg, Genotype
Papers published on a yearly basis
Papers
More filters
TL;DR: It is shown that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7) and provides a powerful tool for studying the viral life cycle and developing antiviral strategies.
Abstract: Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem. Detailed analyses of HCV have been hampered by the lack of viral culture systems. Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture. Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7). Particles have a density of about 1.15–1.17 g/ml and a spherical morphology with an average diameter of about 55 nm. Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by immunoglobulins from chronically infected individuals. The cell culture–generated HCV is infectious for chimpanzee. This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.
2,809 citations
Nagoya City University1, University of Tokyo2, Tokyo Medical and Dental University3, Hokkaido University4, Kyoto Prefectural University of Medicine5, Shinshu University6, Saitama Medical University7, Tottori University8, Kanazawa University9, Ehime University10, Hyogo College of Medicine11, Hitachi12, Yamaguchi University13
TL;DR: A genome-wide association study to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population is reported.
Abstract: Masashi Mizokami and colleagues report a genome-wide association study to hepatitis C treatment response in two Japanese cohorts. They report common variants at IL28B associated with sustained as well as null virologic response following pegylated interferon-alpha and ribavirin combined therapy.
2,097 citations
University of Edinburgh1, National Institutes of Health2, University of Yamanashi3, Food and Drug Administration4, BioMérieux5, Los Alamos National Laboratory6, Innogenetics7, Nagoya City University8, Jichi Medical University9, University of Paris10, University of Giessen11, Chiron Corporation12, Malmö University13
TL;DR: These proposals provide the framework by which the HCV databases store and provide access to data on HCV, which will internationally coordinate the assignment of new genotypes and subtypes in the future.
1,520 citations
TL;DR: Findings indicate that mode of acquisition is an important determinant of HCV viraemia and that patients with low HCVviraemia levels are more likely to respond to interferon in a sustained fashion.
809 citations
TL;DR: The genotype 2a subgenomic replicon was established in Huh7 cells and replicated efficiently with or without G418 selection in a transient replication assay, providing a powerful new tool for researching HCV.
619 citations
Cited by
More filters
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
7,851 citations
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
6,964 citations
01 Jan 2010
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Abstract: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/ Documents/Bookmarked%20Practice%20Guidelines/ HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations.
6,642 citations
01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
4,408 citations